In another initial clinical trial (124) that included patients with advanced pancreatic cancer, MUC-1 showed antigen-specific T-cell responses in 5 of 8 patients (62.5%) who could be evaluated. This evidence concerns the gene MUC1 and familial pancreatic carcinoma.